PMID- 22807536
OWN - NLM
STAT- MEDLINE
DCOM- 20130130
LR  - 20211021
IS  - 1758-1052 (Electronic)
IS  - 0956-4624 (Print)
IS  - 0956-4624 (Linking)
VI  - 23
IP  - 6
DP  - 2012 Jun
TI  - Immune reconstitution inflammatory syndrome in HIV-infected patients with and 
      without prior tuberculosis.
PG  - 419-23
LID - 10.1258/ijsa.2009.009439 [doi]
AB  - We conducted a nested case-control study in a cohort of patients initiating 
      antiretroviral therapy (ART) to identify risk factors and common manifestations 
      of immune reconstitution inflammatory syndrome (IRIS) and to validate the 
      Robertson criteria for IRIS prediction. HIV-infected patients at the Tuberculosis 
      Research Centre clinics, Chennai and Madurai, India, initiating ART between July 
      2004 and June 2005 were prospectively studied. Of 97 patients (62% men, median 
      age 32 years, median CD4 count 63 cells/muL) included, 34 developed IRIS. IRIS was 
      more common in patients with a prior history of tuberculosis (74% versus 52%, P = 
      0.04), median time to development was 46 days and the sensitivity and specificity 
      of the Robertson criteria to predict IRIS were 91% and 22%, respectively. In this 
      population, IRIS was a common event, more so among patients with prior 
      tuberculosis, and neither the rate of CD4 increase nor the Robertson criteria 
      were useful in predicting its development.
FAU - Kumar, S Ramesh
AU  - Kumar SR
AD  - Tuberculosis Research Centre (ICMR), Chennai, India.
FAU - Gopalan, Narendran
AU  - Gopalan N
FAU - Patrawalla, Paru
AU  - Patrawalla P
FAU - Menon, Pradeep
AU  - Menon P
FAU - Mayer, Kenneth
AU  - Mayer K
FAU - Swaminathan, Soumya
AU  - Swaminathan S
LA  - eng
GR  - D43 TW000237/TW/FIC NIH HHS/United States
GR  - D43-TW000237/TW/FIC NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - Int J STD AIDS
JT  - International journal of STD & AIDS
JID - 9007917
RN  - 0 (Anti-HIV Agents)
SB  - IM
MH  - Adult
MH  - Anti-HIV Agents/therapeutic use
MH  - CD4 Lymphocyte Count
MH  - Female
MH  - HIV Infections/drug therapy/*immunology
MH  - Humans
MH  - Immune Reconstitution Inflammatory Syndrome/*virology
MH  - India
MH  - Male
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Sensitivity and Specificity
MH  - Severity of Illness Index
MH  - Tuberculosis/*immunology/*virology
PMC - PMC5592838
MID - NIHMS900265
EDAT- 2012/07/19 06:00
MHDA- 2013/01/31 06:00
PMCR- 2017/09/11
CRDT- 2012/07/19 06:00
PHST- 2012/07/19 06:00 [entrez]
PHST- 2012/07/19 06:00 [pubmed]
PHST- 2013/01/31 06:00 [medline]
PHST- 2017/09/11 00:00 [pmc-release]
AID - 23/6/419 [pii]
AID - 10.1258/ijsa.2009.009439 [doi]
PST - ppublish
SO  - Int J STD AIDS. 2012 Jun;23(6):419-23. doi: 10.1258/ijsa.2009.009439.